Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 185

Related Citations for PubMed (Select 23056499)

1.

AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.

Couto JP, Almeida A, Daly L, Sobrinho-Simões M, Bromberg JF, Soares P.

PLoS One. 2012;7(10):e46869. doi: 10.1371/journal.pone.0046869. Epub 2012 Oct 2.

2.

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.

Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.

Clin Cancer Res. 2006 Mar 15;12(6):1785-93.

3.

Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.

Caccia D, Miccichè F, Cassinelli G, Mondellini P, Casalini P, Bongarzone I.

Mol Cancer. 2010 Oct 18;9:278. doi: 10.1186/1476-4598-9-278.

5.

The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.

Verbeek HH, Alves MM, de Groot JW, Osinga J, Plukker JT, Links TP, Hofstra RM.

J Clin Endocrinol Metab. 2011 Jun;96(6):E991-5. doi: 10.1210/jc.2010-2381. Epub 2011 Apr 6.

PMID:
21470995
6.

Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.

Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, Seregni E, Martinetti A, Laccabue D, Zanchi C, Zunino F.

J Natl Cancer Inst. 2004 Jul 7;96(13):1006-14.

7.

The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.

Scuto A, Krejci P, Popplewell L, Wu J, Wang Y, Kujawski M, Kowolik C, Xin H, Chen L, Wang Y, Kretzner L, Yu H, Wilcox WR, Yen Y, Forman S, Jove R.

Leukemia. 2011 Mar;25(3):538-50. doi: 10.1038/leu.2010.289. Epub 2010 Dec 17.

8.

The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.

Vitagliano D, De Falco V, Tamburrino A, Coluzzi S, Troncone G, Chiappetta G, Ciardiello F, Tortora G, Fagin JA, Ryan AJ, Carlomagno F, Santoro M.

Endocr Relat Cancer. 2010 Nov 30;18(1):1-11. doi: 10.1677/ERC-09-0292. Print 2011 Feb.

9.

Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells.

Gild ML, Landa I, Ryder M, Ghossein RA, Knauf JA, Fagin JA.

Endocr Relat Cancer. 2013 Aug 21;20(5):659-67. doi: 10.1530/ERC-13-0085. Print 2013 Oct.

10.

Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.

Ezzat S, Huang P, Dackiw A, Asa SL.

Clin Cancer Res. 2005 Feb 1;11(3):1336-41.

11.

Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.

De Falco V, Buonocore P, Muthu M, Torregrossa L, Basolo F, Billaud M, Gozgit JM, Carlomagno F, Santoro M.

J Clin Endocrinol Metab. 2013 May;98(5):E811-9. doi: 10.1210/jc.2012-2672. Epub 2013 Mar 22.

PMID:
23526464
12.

Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC.

Kim YR, Byun HS, Won M, Park KA, Kim JM, Choi BL, Lee H, Hong JH, Park J, Seok JH, Kim DW, Shong M, Park SK, Hur GM.

BMC Cancer. 2008 May 23;8:144. doi: 10.1186/1471-2407-8-144.

13.

Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells.

Klubo-Gwiezdzinska J, Jensen K, Costello J, Patel A, Hoperia V, Bauer A, Burman KD, Wartofsky L, Vasko V.

Endocr Relat Cancer. 2012 May 24;19(3):447-56. doi: 10.1530/ERC-12-0046. Print 2012 Jun.

14.

In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.

Bentzien F, Zuzow M, Heald N, Gibson A, Shi Y, Goon L, Yu P, Engst S, Zhang W, Huang D, Zhao L, Vysotskaia V, Chu F, Bautista R, Cancilla B, Lamb P, Joly AH, Yakes FM.

Thyroid. 2013 Dec;23(12):1569-77. doi: 10.1089/thy.2013.0137. Epub 2013 Sep 17.

15.

The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.

Kushchayeva Y, Jensen K, Recupero A, Costello J, Patel A, Klubo-Gwiezdzinska J, Boyle L, Burman K, Vasko V.

J Clin Endocrinol Metab. 2014 May;99(5):E734-45. doi: 10.1210/jc.2013-3369. Epub 2014 Jan 31.

PMID:
24483157
16.

Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.

Drosten M, Hilken G, Böckmann M, Rödicker F, Mise N, Cranston AN, Dahmen U, Ponder BA, Pützer BM.

J Natl Cancer Inst. 2004 Aug 18;96(16):1231-9.

17.

Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice.

Starenki D, Singh NK, Jensen DR, Peterson FC, Park JI.

Cancer Lett. 2013 Oct 1;339(1):144-51. doi: 10.1016/j.canlet.2013.07.006. Epub 2013 Jul 12.

18.

Orthovanadate-induced cell death in RET/PTC1-harboring cancer cells involves the activation of caspases and altered signaling through PI3K/Akt/mTOR.

Gonçalves AP, Videira A, Soares P, Máximo V.

Life Sci. 2011 Sep 12;89(11-12):371-7. doi: 10.1016/j.lfs.2011.07.004. Epub 2011 Jul 23.

PMID:
21807000
19.

Anti-tumor activity of motesanib in a medullary thyroid cancer model.

Coxon A, Bready J, Kaufman S, Estrada J, Osgood T, Canon J, Wang L, Radinsky R, Kendall R, Hughes P, Polverino A.

J Endocrinol Invest. 2012 Feb;35(2):181-90. doi: 10.3275/7609. Epub 2011 Mar 21.

PMID:
21422803
20.

Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.

Petrangolini G, Cuccuru G, Lanzi C, Tortoreto M, Belluco S, Pratesi G, Cassinelli G, Zunino F.

Biochem Pharmacol. 2006 Aug 14;72(4):405-14. Epub 2006 Jun 6.

PMID:
16756963
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk